Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Titel:
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Auteur:
Rosenstock, Julio Frias, Juan Jastreboff, Ania M Du, Yu Lou, Jitong Gurbuz, Sirel Thomas, Melissa K Hartman, Mark L Haupt, Axel Milicevic, Zvonko Coskun, Tamer